글로벌 골형성부전증 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

골형성부전증 치료 시장 분석

골형성 부전증 치료 시장은 매우 취약한 뼈와 잦은 골절을 유발하는 것으로 알려진 유전적 질환 인 골형성 부전증을 관리하기 위한 혁신적인 접근 방식에 초점을 맞춥니다. 비스포스포네이트와 뼈 강화제를 포함한 기존 치료법은 뼈 밀도를 개선합니다. 그러나 유전자 치료 및 세포 치료와 같은 최근의 발전은 골형성 부전증의 근본적인 유전적 원인을 해결하는 것을 목표로 하는 보다 집중적인 접근 방식을 제공합니다. 연구는 또한 개인화된 장기적 솔루션의 잠재력을 제공하는 유전자 편집 기술로 확대되고 있습니다. 인지도 향상과 진단 방법의 발전으로 보건 기관과 정부의 지원이 촉진되어 골형성 부전증과 같은 희귀 질환에 대한 연구가 활성화되었습니다. 지원 정책과 자금 지원은 임상 시험과 혁신적인 치료법에 대한 모멘텀을 주도하여 골형성 부전증 치료 시장에 대한 긍정적인 전망을 제공합니다. 전반적으로, 전문 치료와 원격 진료를 통해 환자 결과를 개선하고 골형성 부전증의 영향을 받는 사람들의 치료 접근성과 삶의 질을 모두 개선하는 데 중점을 두고 있습니다.

골형성부전증 치료 시장 규모

글로벌 골형성부전증 치료 시장 규모는 2023년에 7억 2,280만 달러로 평가되었으며, 2031년까지 8억 7,381만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 2.40%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

골형성부전증 치료 시장 동향

“ 유전자 치료 및 표적 생물학 분야의 혁신”

골형성 부전증 치료 시장은 이 질환에 대한 인식 증가와 치료 옵션의 발전에 힘입어 상당한 성장을 경험하고 있습니다. 유전자 치료 및 표적 생물학적 제제와 같은 혁신은 잠재적인 게임 체인저로 부상하여 골형성 부전증을 관리하는 데 더 효과적이고 개인화된 접근 방식을 제공합니다. 주목할 만한 추세 중 하나는 환자의 뼈 밀도를 높이고 골절률을 줄이는 데 효과적인 것으로 입증된 비스포스포네이트의 사용 증가입니다. 이러한 추세는 환자 결과를 우선시하는 증거 기반 치료법으로의 광범위한 전환을 반영합니다. 지속적인 연구 및 개발을 통해 시장은 골형성 부전증의 영향을 받는 개인의 치료 효능을 높이고 삶의 질을 개선하는 데 중점을 두고 더욱 발전할 준비가 되었습니다. 전반적인 전망은 긍정적이며 충족되지 않은 의료적 요구 사항을 해결하려는 노력을 강조합니다.

보고 범위 및 골형성부전증 치료 시장 세분화

골형성부전증 치료 시장 정의

Osteogenesis imperfecta treatment encompasses various medical and therapeutic approaches aimed at managing the genetic disorder characterized by fragile bones. The treatment focuses on increasing bone strength, reducing fracture frequency, and improving quality of life. Options include medications such as bisphosphonates, surgical interventions, physical therapy, and supportive care to enhance mobility and provide assistance in daily activities.

Osteogenesis Imperfecta Treatment Market Dynamics

Drivers

• Rising Prevalence of Genetic Testing

Advances in genetic testing and imaging technologies play a crucial role in enhancing the accuracy of osteogenesis imperfecta diagnoses, thereby facilitating timely treatment interventions. Genetic testing allows for precise identification of the specific mutations associated with osteogenesis imperfecta, enabling healthcare providers to tailor treatment strategies to individual patients. Additionally, advanced imaging techniques, such as high-resolution X-rays and MRI, provide detailed insights into bone structure and density, helping to assess the severity of the condition more accurately. These technological improvements lead to earlier diagnosis and intervention and drive demand within the osteogenesis imperfecta treatment market as more patients seek effective management options.

•  Increasing Awareness Among Healthcare Professionals

Increased awareness among healthcare providers and the general public regarding osteogenesis imperfecta is a significant driver of growth in the osteogenesis imperfecta treatment market. As knowledge about the condition spreads, healthcare professionals are better equipped to recognize its symptoms and refer patients for appropriate testing and diagnosis. This heightened awareness also encourages families to seek medical advice sooner when they observe signs of bone fragility in themselves or their children. Early diagnosis and intervention can lead to timely treatment, which is crucial for improving patient outcomes. As a result, the growing awareness contributes to an expanding patient population seeking effective therapies for osteogenesis imperfecta.

Opportunities

• Advancements in Telehealth Services

The growing acceptance of telehealth services presents a valuable opportunity in the osteogenesis imperfecta treatment market by enhancing patient management and education. Telehealth platforms allow individuals with osteogenesis imperfecta to consult with specialists without the need for extensive travel, ensuring they receive timely medical advice and support. This improved access to healthcare professionals facilitates personalized treatment plans and ongoing monitoring, which are crucial for managing the condition effectively. Moreover, telehealth enables educational resources to be shared easily, empowering patients and their families with knowledge about the disorder and its management. As a result, the integration of telehealth services can significantly improve patient outcomes and drive demand for effective osteogenesis imperfecta treatments.

• Innovative Drug Delivery Systems

Research into novel drug delivery methods, including nanoparticles and sustained-release formulations, offers a significant opportunity for enhancing the osteogenesis imperfecta treatment market. These advanced delivery systems can improve the bioavailability and targeted delivery of medications, ensuring that therapeutic agents are released in a controlled manner over an extended period. By optimizing how drugs are administered, these methods can enhance treatment efficacy and minimize side effects, leading to better patient compliance. Furthermore, improved delivery systems can facilitate the administration of existing therapies, making them more accessible and user-friendly for patients. This innovation boosts the effectiveness of osteogenesis imperfecta treatments and encourages healthcare providers to adopt these advanced methods, ultimately expanding the market.

Restraints/Challenges

• High Research and Development Costs

Developing new treatments for rare diseases such as osteogenesis imperfecta presents a significant challenge due to the prohibitively high costs associated with research and development. The complexity of rare diseases often requires extensive clinical trials, sophisticated technologies, and long timelines to ensure safety and efficacy, all of which contribute to escalating expenses. This financial burden may deter pharmaceutical companies from investing in the development of innovative therapies, particularly when potential market sizes are limited. As a result, the lack of investment can hinder the introduction of effective treatment options for individuals with osteogenesis imperfecta, leaving a gap in available therapies and impacting patient care.

• Competition in Rare Disease

Increased competition within the rare disease space, particularly for conditions such as osteogenesis imperfecta, poses a significant restraint on the treatment market. As more pharmaceutical companies develop and launch therapies, the resulting pricing pressures can complicate efforts to maintain profitability. Companies may feel compelled to reduce prices to remain competitive, which can strain their financial resources and hinder investment in research and development for new therapies. While ensuring patient access to treatments is crucial, balancing this need with the financial viability of companies becomes challenging. Consequently, the competitive landscape can impact the sustainability of treatment options available to individuals with osteogenesis imperfecta.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Osteogenesis Imperfecta Treatment Market Scope

The market is segmented on the basis of drug class, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Teriparatide
• Denosumab
• Others

Route of Administration

• Oral
• Intravenous
• Subcutaneous

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Osteogenesis Imperfecta Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug class, route of administration, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the osteogenesis imperfecta treatment market, driven by the significant presence of leading pharmaceutical companies and a robust commitment to research and development. This region benefits from advanced healthcare infrastructure and strong investment in innovative therapies. As a result, North America is well-positioned to provide effective treatment solutions for individuals affected by osteogenesis imperfecta.

The Asia-Pacific region is anticipated to experience substantial growth in the osteogenesis imperfecta treatment market from 2024 to 2031, fueled by a rapid adoption of innovative products. This expansion is also driven by the rising number of patients diagnosed with osteogenesis imperfecta in the region. As awareness and access to effective treatments improve, the demand for therapeutic solutions is expected to increase significantly.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Osteogenesis Imperfecta Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Osteogenesis Imperfecta Treatment Market Leaders Operating in the Market Are:

• BioSenic SA (Belgium)
• Bristol-Myers Squibb Company (U.S.)
• Mereo BioPharma Group PLC (U.K.)
• Eli Lilly and Company (U.S.)
• Amgen Inc (U.S.)
• Midas Pharma GmbH (Germany)
• LGM Pharma (U.S.)
• Cipla (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Viatris Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Aurobindo Pharma (India)
• Jubilant Pharmova Limited (India)

Latest Developments in Osteogenesis Imperfecta Treatment Market

• In January 2024, Bone Therapeutics launched a Phase I/IIa clinical trial for its allogeneic cell therapy product, ALLOB, targeting patients with osteogenesis imperfecta. The trial aims to assess ALLOB's effectiveness in enhancing bone strength and minimizing the risk of fractures in individuals suffering from this condition. This initiative marks a significant step forward in the development of innovative therapeutic solutions for osteogenesis imperfecta, with the potential to improve patient outcomes
• In March 2023, Mereo BioPharma Group plc revealed encouraging topline results from its Phase 2b ASTER study, which focused on setrusumab, a novel anti-sclerostin antibody aimed at treating adults with osteogenesis imperfecta. The study demonstrated promising efficacy and safety outcomes, highlighting the potential of setrusumab as a therapeutic option for managing this rare bone disorder. These findings represent a significant advancement in the development of targeted treatments for individuals affected by osteogenesis imperfecta
• In July 2023, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company dedicated to developing innovative therapies, announced that the first patients have been treated in its late-stage clinical trials assessing setrusumab in pediatric and young adult patients with osteogenesis imperfecta sub-types I, III, and IV. The Phase 3 segment of the pivotal Phase 2/3 Orbit study is focused on comparing the effects of setrusumab versus placebo on the annualized clinical fracture rate in patients aged 5 to under 26 years. Additionally, the newly initiated Phase 3 Cosmic study is actively evaluating setrusumab against intravenous bisphosphonate therapy for its impact on the total fracture rate in patients aged 2 to under 5 years
• In October 2022, the Osteogenesis Imperfecta Federation Europe (OIFE) announced its re-establishment as a new legal entity in Belgium, marking a significant transition for the organization. This move involved dissolving its previous legal status in the Netherlands, streamlining its operations and governance structure. The reorganization aims to enhance the federation's effectiveness in advocating for individuals affected by osteogenesis imperfecta and to strengthen its commitment to improving patient support and awareness across Europe
• 2021년 10월, 종양학과 희귀 질환을 전문으로 하는 임상 단계의 바이오제약 회사인 Mereo BioPharma Group plc는 Osteogenesis Imperfecta Federation Europe(OIFE)와 Osteogenesis Imperfecta Foundation(OIF)과 협력하여 지금까지 가장 큰 규모의 글로벌 데이터 수집 노력에 대한 등록을 완료했습니다. OI(Osteogenesis Imperfecta)가 영향을 받는 개인, 가족 및 간병인에게 미치는 영향에 대한 데이터 수집 노력입니다. IMPACT 설문 조사는 약 65개국에서 3개월 기간 내에 2,200건 이상의 응답을 수집하여 이 상태의 광범위한 관련성을 강조했습니다. 이 설문 조사의 결과는 OI에 대한 진단, 치료 및 관리를 개선하고 새로운 치료법의 적시 평가 및 가용성을 용이하게 하는 것을 목표로 하는 미래의 협력 이니셔티브에 정보를 제공할 것입니다.

SKU-46387